# Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

> **NCT07249905** · PHASE1,PHASE2 · RECRUITING · sponsor: **ModeX Therapeutics, An OPKO Health Company** · enrollment: 180 (estimated)

## Conditions studied

- Lymphoma
- Waldenström Macroglobulinemia (WM)
- DLBCL - Diffuse Large B Cell Lymphoma
- PMBCL
- HGBCL
- FL Lymphoma
- Lymphoplasmacytic Lymphoma
- Follicular Lymphoma (FL)

## Interventions

- **DRUG:** MDX2003

## Key facts

- **NCT ID:** NCT07249905
- **Lead sponsor:** ModeX Therapeutics, An OPKO Health Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-13
- **Primary completion:** 2028-01
- **Final completion:** 2030-04
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07249905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07249905, "Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07249905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*